Carmell Therapeutics Stock Analysis
| CTCX Stock | 0.28 0.02 7.69% |
Carmell Therapeutics is fairly valued with Real Value of 0.27 and Hype Value of 0.28. The main objective of Carmell Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Carmell Therapeutics is worth, separate from its market price. There are two main types of Carmell Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Carmell Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Carmell Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Carmell Stock trading window is adjusted to America/New York timezone.
Carmell |
Carmell Stock Analysis Notes
About 34.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.91. Some equities with similar Price to Book (P/B) outperform the market in the long run. Carmell Therapeutics had not issued any dividends in recent years. For more info on Carmell Therapeutics please contact the company at 919 313 9633 or go to https://www.carmellcosmetics.com.Carmell Therapeutics Investment Alerts
| Carmell Therapeutics generated a negative expected return over the last 90 days | |
| Carmell Therapeutics has high historical volatility and very poor performance | |
| Carmell Therapeutics has some characteristics of a very speculative penny stock | |
| Carmell Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (15.45 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Carmell Therapeutics generates negative cash flow from operations | |
| Carmell Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 34.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Meteora Capital, LLC Reduces Stake in Carmell Corp |
Carmell Therapeutics Upcoming and Recent Events
Earnings reports are used by Carmell Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Carmell Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.77 M.Carmell Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.25) | |
| Return On Capital Employed | (0.21) | (0.19) | |
| Return On Assets | (0.24) | (0.25) | |
| Return On Equity | (0.62) | (0.59) |
Management Efficiency
Carmell Therapeutics has return on total asset (ROA) of (0.8464) % which means that it has lost $0.8464 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7639) %, meaning that it created substantial loss on money invested by shareholders. Carmell Therapeutics' management efficiency ratios could be used to measure how well Carmell Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.25 in 2024. Return On Capital Employed is likely to rise to -0.19 in 2024. At this time, Carmell Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 62.8 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 952 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.25 | 2.36 | |
| Tangible Book Value Per Share | 2.24 | 2.36 | |
| Enterprise Value Over EBITDA | (2.71) | (2.85) | |
| Price Book Value Ratio | 1.70 | 1.78 | |
| Enterprise Value Multiple | (2.71) | (2.85) | |
| Price Fair Value | 1.70 | 1.78 | |
| Enterprise Value | 41.2 M | 39.2 M |
Carmell Therapeutics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Operating Margin (96.71) | Beta 0.314 | Return On Assets (0.85) | Return On Equity (1.76) |
Technical Drivers
As of the 29th of November, Carmell Therapeutics shows the Risk Adjusted Performance of (0.02), standard deviation of 14.02, and Mean Deviation of 8.37. Carmell Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Carmell Therapeutics Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Carmell Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Carmell Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Carmell Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Carmell Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Carmell Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Carmell Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Carmell Therapeutics Predictive Daily Indicators
Carmell Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Carmell Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Carmell Therapeutics Forecast Models
Carmell Therapeutics' time-series forecasting models are one of many Carmell Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Carmell Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Carmell Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Carmell Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Carmell shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Carmell Therapeutics. By using and applying Carmell Stock analysis, traders can create a robust methodology for identifying Carmell entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Carmell Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Sync Your Broker Now
Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
| All Next | Launch Module |
Additional Tools for Carmell Stock Analysis
When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.